Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06865144 · ClinicalTrials.gov registry record · Phase 4
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
A Phase 4 study of Primary Open Angle Glaucoma or Ocular Hypertension, sponsored by East Coast Institute for Research.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06865144: Recruiting Phase 4 study of Primary Open Angle Glaucoma or Ocular Hypertension, sponsored by East Coast Institute for Research.
NCT06865144 is a Phase 4 study of Primary Open Angle Glaucoma or Ocular Hypertension that is actively recruiting participants, run by East Coast Institute for Research. The registered enrollment target is 70 participants, above the 41-participant average among 3 other Primary Open Angle Glaucoma or Ocular Hypertension trials with a reported enrollment target (71% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06865144, a Phase 4 study of Primary Open Angle Glaucoma or Ocular Hypertension, is actively recruiting participants, sponsored by East Coast Institute for Research.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.
Primary Outcome
Between-group difference in change in mean diurnal IOP
Conditions Studied
Interventions
- DRUG Netarsudil ophthalmic solution 0.02%
- DRUG Artificial tears
Study Locations (1)
Florida
- East Coast Institute for Research at Florida Eye Specialists - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 4 |
What NCT06865144 shows while recruiting
NCT06865144 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 41-participant average among 3 other Primary Open Angle Glaucoma or Ocular Hypertension trials with a reported enrollment target (71% higher).
The record links to 1 condition, with Primary Open Angle Glaucoma or Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Netarsudil ophthalmic solution 0.02% is the first listed.
NCT06865144 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06865144 about?
NCT06865144 is a clinical study titled "Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT". The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.
What is the current status of trial NCT06865144?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2025-06-27. Estimated completion is 2026-04-01.
What conditions does trial NCT06865144 study?
This clinical trial studies the following conditions: Primary Open Angle Glaucoma or Ocular Hypertension.
What interventions are being tested in trial NCT06865144?
The interventions under investigation include: Netarsudil ophthalmic solution 0.02% (DRUG), Artificial tears (DRUG).
Who is sponsoring clinical trial NCT06865144?
This trial is sponsored by East Coast Institute for Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06865144 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Open Angle Glaucoma or Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
RECRUITING
-
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI